Prøve GULL - Gratis
'For good technology investments, benefits and cost-efficiencies outweigh cost factors overtime'
BioSpectrum Asia
|BioSpectrum Asia Sep 2021
Recent innovations in the industry are, demonstrably, supporting hospitals and healthcare workers in planning for safer and more efficient use of their resources, while minimising waste. Better still, these systems can even help prevent the spread of viruses in hospitals where frontline workers are at great risk. With the increasing concerns around the Asia Pacific (APAC) region, BioSpectrum Asia spoke to healthcare expert, Dirk Dumortier, Head of Business Development Smart-City and Healthcare (Asia Pacific), Alcatel-Lucent Enterprise (ALE), Singapore on prospects and gateways towards progressive healthcare system for Asia-Pacific regions. Edited excerpts;
Dirk Dumortier, Head of Business Development Smart-City and Healthcare (Asia Pacific), Alcatel-Lucent Enterprise, Singapore
Could you brief South East Asia’s healthcare exigency and enduring strategies to build a resilient model?
The global pandemic has exerted considerable stress on our healthcare system and exposed fundamental challenges that need to be resolved urgently. In countries across Southeast Asia battling a resurgence of the COVID-19 virus spread, hospitals are grappling with a widespread shortage of medical resources and trained staff. Front-liners are faced with the herculean task of delivering patient care while managing administrative tasks.
Meanwhile, we also see countries like Singapore struggling with rising healthcare bills due to increased resource consumption, exacerbated by the pandemic and a rapidly ageing population.
It is crucial that healthcare organisations look immediately into enduring strategies to boost their resilience for the long fight ahead. Healthcare organisations must consider how they can digitalise and adopt technologies to cope with rising costs, better manage resources and create a more efficient and safer environment for patients and staff.
Only then, can we prevail in the battle of endurance against the pandemic, as well as be better equipped to weather future crises.
What are the common hurdles in introducing technology to the industry, and how can these be overcome?
The first hurdle to any technology investment decision is usually cost. Decision makers at healthcare organisations may also be concerned with longer-term requirements, such as IT and support teams, maintenance, and upkeep.
Denne historien er fra BioSpectrum Asia Sep 2021-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Translate
Change font size
